Immunome Inc.
Close on Oct 19, 2026
- Market cap
- $1.90B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 19, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | $2.36M | $-0.60 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 9, 2023 | Before market open | – | – | – |
Press releases
Announcements Immunome filed with the SEC
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Immunome Announces Proposed Public Offering of Common Stock
Other events · EX-99.1 to Form 8-K
Immunome Announces Pricing of Public Offering of Common Stock
Other events · EX-99.2 to Form 8-K
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Targeted Therapeutics December 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
Reports Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Proposed Public Offering of Common Stock
Other events · EX-99.1 to Form 8-K
Pricing of Upsized Public Offering of Common Stock
Other events · EX-99.2 to Form 8-K
Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
EFFECTIVE AS OF: OCTOBER 3, 2024
Other events · EX-99.1 to Form 8-K
Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Results of operations · EX-99.1 to Form 8-K
Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
Material agreement · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
We are a biopharmaceutical company focused on the development of targeted
Results of operations · Other events · EX-99.1 to Form 8-K
in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, together with
Results of operations · Other events · EX-99.2 to Form 8-K
Immunome To Acquire AL102, A Phase 3 Asset for
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Immunome Corporate Presentation January 11, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Immunome Corporate Presentation November 15, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Immunome Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Immunome and Morphimmune Announce Successful
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Immunome Reports Second Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation.
Other events · EX-99.1 to Form 8-K
Placement Investment of $125 Million
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
CONFIDENTIAL - DO NOT DISTRIBUTE
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Immunome Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
665 Stockton Drive, Suite 300 | Exton, PA
Other events · EX-99.1 to Form 8-K
AbbVie and Immunome Announce Strategic
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Harnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com Copyright © 2023 Immunome, Inc. All rights reserved.
Material agreement · Other events · EX-99.1 to Form 8-K
Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Immunome Reports Second Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1
Other events · EX-99.1 to Form 8-K
Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K